Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

* Histologic or cytologic diagnosis of a malignant neoplasm (solid tumor) arising from any primary site with the exception of bone marrow or lymphoid tissue
* Recurrent or progressive disease after chemotherapy or radiotherapy

  * Chemotherapy or radiotherapy-naive disease allowed if patient is not a candidate for standard treatment either due to comorbidities or lack of willingness to undergo standard treatment
* Measurable disease

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 30 mL/min
* Bilirubin ≤ 2 mg/dL
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No active concurrent invasive malignancy
* No peripheral neuropathy ≥ grade 2 within the past 14 days
* No hypersensitivity to bortezomib, boron, mannitol, any of the cyclooxygenase (COX-2) inhibitors, sulfa drugs, or other nonsteroidal anti-inflammatory drugs (NSAIDs)
* No active gastrointestinal (GI) ulcers OR history of GI bleeding resulting from prior therapy with NSAIDs

PRIOR CONCURRENT THERAPY:

* At least 2 weeks since completion of prior radiotherapy
* No prior bortezomib
* No other concurrent investigational agents
* No concurrent chemotherapy, radiotherapy, or anticancer surgery
* No concurrent immune-enhancing therapy